evipedia.ai
← Back

Pinealon for Health & Longevity

Evidence Review created on 10/26/2026 using AI4L / Opus 5.5

Also known as: EDR Peptide, EDR, Glu-Asp-Arg, Glutamyl-Aspartyl-Arginine, T-33

Motivation

Pinealon is a lab-made peptide, a chain of just three amino acids, developed in Russia as one of a family of so-called peptide bioregulators. Its developers propose that such tiny peptides enter cells and adjust which genes are switched on, with the brain as pinealon’s main target. Interest centers on whether it can preserve the aging brain’s mental performance and slow measures of biological aging.

The peptide was identified within an older Russian brain-extract medicine and has been sold in Russia for years as a dietary supplement, while in Western countries it circulates mainly as an injectable research chemical. It drew wider attention when popular longevity podcasts discussed its use for longer dreaming sleep. Almost all published research on it comes from the group that created it.

This review examines what the laboratory, animal and human studies show about pinealon’s benefits and risks, how strong and how independent that evidence is, and which practical questions about dosing, sourcing and monitoring arise for health-focused adults weighing it as part of a longevity strategy.

Benefits - Risks - Protocol - Conclusion

Expert commentary and a developer review that discuss pinealon by name in depth.

Only two items qualify: most other pinealon content online comes from peptide vendors, dosing-protocol sites or AI-generated reference pages, which fall outside the eligible content types. No pinealon content was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io: their on-site searches and web searches returned no matches, and Life Extension’s site search could not be rendered on any retrieval tier.

Grokipedia

Pinealon

An AI-written overview of pinealon’s chemistry, Cortexin origin, proposed mechanisms and Russian studies; useful orientation, although it repeats developer claims such as the absence of side effects, with only brief caveats about thin evidence.

Examine

No Examine article on pinealon exists.

ConsumerLab

No ConsumerLab article on pinealon exists.

Systematic Reviews

No systematic reviews or meta-analyses for Pinealon were found on PubMed as of 10/26/2026.

Neither the claimed effect nor the principal risk of pinealon is therefore represented by a systematic review or meta-analysis.

Mechanism of Action

Pinealon (Glu-Asp-Arg) is a tripeptide (three linked amino acids) its developers classify as an epigenetic regulator (a substance that changes gene activity without altering the DNA sequence).

  • Nuclear entry and DNA binding: Fluorescence-labeled pinealon entered nuclei of cultured human cells and bound specific DNA sequences in cell-free tests (Fedoreyeva 2011). Independent biophysicists found it lodges partly in DNA’s major groove (Silanteva 2019). Computer docking (simulated molecular binding) predicts sites in the promoters of CASP3 (gene for caspase-3, a cell-death enzyme), SOD2 and GPX1 (genes for antioxidant enzymes), PPARA and PPARG (genes regulating fat metabolism and inflammation) and APOE (a gene for a lipid-transport protein) (Khavinson 2021).
  • Oxidative stress: In neurons and immune cells, pinealon limited reactive oxygen species (ROS, unstable oxygen molecules that damage cells) and delayed activation of ERK1/2 (extracellular signal-regulated kinases, stress-signaling enzymes) (Khavinson 2011).
  • Neurotransmitters: It increased serotonin expression in aging cortex-cell cultures (Khavinson 2014).

Competing view: The developers’ own work found no direct antioxidant activity and higher intracellular ROS with these peptides (Kozina 2008), and brain caspase-3 rose rather than fell in one rat study (Mendzheritskiĭ 2011). Gene-regulation claims rest on docking and cell-free binding.

Pharmacology: No pharmacokinetic study exists, so half-life, tissue distribution and selectivity are unmeasured. As an unmodified peptide it is presumably degraded by peptidases (protein-cutting enzymes), not CYP (cytochrome P450, liver drug-metabolizing) enzymes. Gut uptake via the PEPT1 and LAT1 transporters (cell-membrane carriers for small peptides and amino acids) is proposed from docking alone (Khavinson 2023).

Historical Context & Evolution

Pinealon traces to Cortexin, a calf brain-cortex polypeptide extract used in Russia as a neuroprotective drug. Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology synthesized short peptides from such extracts; EDR (pinealon’s one-letter amino-acid code) is described as a Cortexin derivative (Kuznik 2019). Despite its name, it is not a pineal-gland product.

  • Original intended use: Correction of age-related brain dysfunction in Russian geriatric and occupational medicine (Khavinson 2020), mainly as oral capsules listed as a dietary supplement (RLS register).
  • Early findings (2008–2015): Better hypoxia (low-oxygen) tolerance in rats (Kozina 2008), protection of offspring of rats with hyperhomocysteinemia (high blood homocysteine) (Arutjunyan 2012), and uncontrolled human reports of improved biological-age scores (Meshchaninov 2015).
  • Shift to Alzheimer’s models (2017 onward): Work moved to synapse preservation in neurons exposed to amyloid (the protein forming Alzheimer’s plaques) (Kraskovskaya 2017).

Why it reached health optimization: The bioregulator concept holds that short tissue-specific peptides restore gene expression that declines with age, which made pinealon a candidate geroprotector (a substance slowing aging processes). In 2024 its use for sleep was discussed on the Huberman Lab podcast (Huberman Lab episode).

What changed: In 2026 the first non-Russian animal test found only a non-significant memory trend (Marín-Jerez 2026). No study has confirmed or refuted the human claims; their standing depends on replication outside the originating group.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no randomized or placebo-controlled human trial of pinealon has been published, and the human reports are uncontrolled series from one research network.

Medium 🟩 🟩

No benefit reaches Medium: no single controlled human trial exists, and the available human reports lack a comparison group or mix pinealon with another peptide.

Low 🟩

Cognitive Function After Brain Injury and in Aging

Memory reportedly improved in 72 brain-injury patients given pinealon plus standard care, per the developers’ summary (Khavinson 2020), and nervous-system activity in 32 adults with organic brain syndrome (physically caused brain dysfunction) split between pinealon and Vesugen (Meshchaninov 2015). Neither used a placebo. Rats learned mazes faster (Mendzheritski 2013).

Magnitude: Not quantified in available studies. The indexed reports state significance without group figures, and the brain-injury study is not indexed in PubMed.

Resilience to Occupational Stress

Among 150 professional truck drivers, peptide courses reportedly improved psychoemotional scores and borderline mental-health symptoms, best when pinealon was combined with Vesugen, so part of this evidence is indirect (Bashkireva 2012). Locomotive crews on pinealon alone improved adaptation indices (Nazimko 2012).

Magnitude: Not quantified in available studies. The abstracts report only p-values (probabilities that a result arose by chance) of 0.001–0.05, without group means or effect sizes.

Speculative 🟨

Slower Biological-Age Indices

Russian composite biological-age scores improved after pinealon courses (Meshchaninov 2015; Myakotnykh 2016). These uncontrolled studies used scores unvalidated against outcomes. No lifespan study of pinealon exists in any species.

Neuronal Protection From Oxidative and Hypoxic Stress ⚠️ Conflicted

Pinealon lowered ROS in cultured cells (Khavinson 2011) and improved rat hypoxia tolerance (Kozina 2008), yet another cell study found raised ROS (Kozina 2008). The net signal is inconsistent, from animal and cell studies only.

Synapse Preservation in Alzheimer’s Disease Models

In amyloid-exposed mouse neurons, EDR restored mature dendritic spines (synapse sites) (Kraskovskaya 2017). In Alzheimer-model mice, spine density rose 11% without significant memory-circuit improvement (Khavinson 2021). Animal data only.

Longer Rapid Eye Movement (REM) Sleep

Use for longer REM (dreaming-stage) sleep rests on personal accounts discussed in a Huberman Lab episode. EDR raised serotonin expression in cortex-cell cultures (Khavinson 2014). The basis is anecdotal and mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No human genetic data exist. Docking places EDR binding sites in the APOE promoter (Khavinson 2021); whether carriers of APOE ε4 (a gene variant that raises Alzheimer’s risk) respond differently is untested.
  • Baseline antioxidant-enzyme activity: In rats, per the developers’ review, pinealon raised SOD2 and GPX1 enzyme activity only in hypoxia-sensitive animals; hypoxia-resistant animals with high baseline activity gained nothing (Khavinson 2020). Low baseline reserve may predict a larger response.
  • Sex: In Alzheimer-model mice, EDR restored spine density in both sexes, but mature-spine restoration appeared only in males, which had more severe pathology (Khavinson 2021). Human cohorts were mostly men, such as truck drivers (Bashkireva 2012); female response is essentially unstudied.
  • Pre-existing conditions: Reported human benefits come from people with organic brain syndrome and polymorbidity (several chronic diseases at once) (Meshchaninov 2015); healthy, cognitively intact adults have not been studied.
  • Age: Human participants were 41–83 years old (Meshchaninov 2015). The independent mouse screen used middle-aged animals, and its authors suggest older animals might show larger effects (Marín-Jerez 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the only human harm data are one uncontrolled 32-person report, and the remaining signals come from animal and cell studies.

Medium 🟥 🟥

No risk reaches Medium: the human harm signal comes from a single uncontrolled case series that pooled pinealon with Vesugen and had no comparison group.

Low 🟥

Suppressed Blood-Forming Stem Cells

In 32 adults given pinealon or Vesugen, circulating CD34+ cells (blood-forming stem cells) fell, which the authors read as inhibited hematopoiesis (blood-cell production) (Meshchaninov 2015). The study was uncontrolled and pooled both peptides. A 110-person comparison rated peptide courses among the safest on biochemical and immunological parameters (Myakotnykh 2016).

Magnitude: Not quantified in available studies. The abstract reports a significant decrease without figures, and the study had no placebo or comparison group.

Speculative 🟨

Pro-Oxidant Shift ⚠️ Conflicted

In one uncontrolled report, patients showed pro-oxidant chemiluminescence (oxidation-linked light emission) (Meshchaninov 2015); cell studies found ROS rising (Kozina 2008) and falling (Khavinson 2011). The net signal, from isolated reports and mechanistic data, is unresolved.

Unknown Long-Term Effects on Cell Proliferation

Pinealon modulated the cell cycle at higher concentrations (Khavinson 2011) and stimulated skin-cell proliferation in rat tissue cultures (Voicekhovskaya 2012). Effects on abnormal cells are untested; the basis is mechanistic.

Contamination and Injection Reactions From Research-Grade Products

Injectable pinealon lacks human-use quality standards. The FDA (Food and Drug Administration) links impurities in other compounded peptides to immunogenicity (immune reactions) (FDA Category 2 list). Basis: analogy; no pinealon reports exist.

Adverse Behavioral Changes in Animals

In old rats given pinealon before carotid occlusion (blocked neck arteries), exploratory, motivational and motor behavior fell and brain caspase-3 rose (Mendzheritskiĭ 2011). The basis is one animal study.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Pinealon is not known to use CYP enzymes, so common variants such as CYP2D6 (a drug-metabolizing liver enzyme) poor-metabolizer status are not expected to alter exposure.
  • Baseline blood counts: Because circulating CD34+ cells fell in one report (Meshchaninov 2015), people starting with low white-cell, hemoglobin or platelet counts have less reserve if this suppression is real.
  • Sex: No sex-specific adverse data exist. Women were a minority of the 32-person cohort (Meshchaninov 2015), and no pregnancy data exist.
  • Pre-existing conditions: A history of cancer raises a theoretical concern given proliferation signals (Voicekhovskaya 2012); bone-marrow disorders raise concern given the stem-cell signal. Neither group has been studied.
  • Age: The only human safety data come from adults aged 41–83, in whom circulating CD34+ cells fell (Meshchaninov 2015); bone-marrow reserve declines with age, so any suppression of blood-cell production would matter more at the older end.

Key Interactions & Contraindications

Documented interactions:

  • Vesugen (Lys-Glu-Asp, a vascular peptide bioregulator): No interaction found: courses combining the two ranked among the safest options on biochemical and immunological parameters and improved biological-age scores most (Myakotnykh 2016); truck drivers’ psychoemotional indices also improved most with the combination (Bashkireva 2012).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Myelosuppressive drugs (marrow-suppressing drugs such as methotrexate, azathioprine, chemotherapy): Inferred from the CD34+ decline (Meshchaninov 2015): possible additive suppression of blood-cell production. A complete blood count (CBC) before and during combined use detects it.
  • Serotonergic antidepressants (SSRIs, selective serotonin reuptake inhibitors, e.g., sertraline; MAOIs, monoamine oxidase inhibitors, e.g., phenelzine): Inferred from raised serotonin expression in cortex cells (Khavinson 2014): possible serotonin excess with agitation, tremor or sweating; symptom checks after starting detect it.
  • PEPT1-transported drugs (valacyclovir, cephalexin, ACE inhibitors, blood-pressure drugs blocking angiotensin-converting enzyme, such as lisinopril): Inferred from transporter docking (Khavinson 2023): competition for gut uptake could reduce absorption of either. Separating doses by several hours avoids overlap.
  • Sleep medications and OTC (over-the-counter) sleep aids (zolpidem, diphenhydramine, melatonin): Inferred from pinealon’s claimed serotonin-mediated sleep effect: possible additive sedation or altered sleep architecture. Introducing one agent at a time clarifies effects.
  • Other peptide bioregulators (epitalon, Cortagen, Cortexin): Inferred from a shared proposed DNA-binding mechanism (Khavinson 2021): possible additive, unpredictable clinical effects, so any adverse event cannot be attributed to one agent. Staggered starts allow attribution.
  • Sleep-promoting supplements (glycine, magnesium): Inferred from pinealon’s claimed sleep effect and their frequent combined use for sleep: possible additive sedation or next-day drowsiness. Adding them after pinealon’s effect is known separates the contributions.
  • Intermittent hypoxia or altitude training: Inferred from antihypoxic effects in rats (Kozina 2008): pinealon could blunt the low-oxygen signal that drives training adaptation. Tracking training markers during courses reveals any blunting.

Populations who should avoid Pinealon:

  • Pregnancy and breastfeeding: Inferred from pinealon’s proposed gene-expression effects on developing tissue; the only developmental data come from rat offspring (Arutjunyan 2012); no human data.
  • Active or recent cancer: Inferred from cell-cycle and proliferation effects in cell and tissue cultures (Khavinson 2011); no human data.
  • Bone-marrow failure or cytopenias (low blood counts): Inferred from the CD34+ decline in one uncontrolled report (Meshchaninov 2015); no controlled data.
  • Children and adolescents: Inferred from proposed gene-expression effects on growing tissue; no pediatric data exist.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Third-party verified product: Batches with independent HPLC (high-performance liquid chromatography) purity and mass-spectrometry identity certificates reduce the risk of contamination, wrong peptide or underdosing in unregulated research-grade products.
  • Oral route as used in human studies: The oral form used in human reports (Nazimko 2012) avoids injection-site infection and the immunogenicity concerns FDA raises for impure injectable peptides (FDA Category 2 list).
  • Blood-count surveillance: A CBC before and after each course detects possible suppression of blood-forming cells (Meshchaninov 2015). No source gives a stopping threshold; values below the laboratory reference range prompt stopping in common practice.
  • Short, defined courses: Two-week courses as in the cited protocol (Nazimko 2012) cap cumulative exposure to unknown long-term gene-expression and proliferation effects.
  • Cancer screening current: Avoiding pinealon during active or recent cancer and keeping age-appropriate screening current reduces the theoretical risk of stimulating proliferating abnormal cells.
  • One new agent at a time: Starting pinealon alone, without other peptides or sleep aids, for at least one course lets any adverse effect, such as sleep disturbance or injection reaction, be attributed and reversed.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycling, titration) reflect common practice.

  • Oral capsule approach (Russian bioregulator practice): 100 µg twice daily for two weeks in locomotive crew workers (Nazimko 2012); popularized by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology.
  • Injectable research-peptide approach (US peptide clinics): Discussed by peptide clinician Craig Koniver on Huberman Lab (Huberman Lab episode); no trial, label or named practitioner has published a human injectable dose, so community figures are not given here.
  • Animal reference dose: 30 mg/kg intraperitoneally (injected into the abdominal cavity) twice weekly for eight weeks in mice (Marín-Jerez 2026); this is not a human dose.
  • Time of day: The cited oral protocol specifies twice-daily use (Nazimko 2012); morning and evening spacing is common practice, and sleep-focused users take pinealon in the evening.
  • Half-life: No human or animal pharmacokinetic study exists; plasma half-life and brain entry are unmeasured, and the developers infer blood-brain barrier passage by analogy with other tripeptides and from their own mouse results (Khavinson 2021).
  • Single vs. split dosing: The only human protocol with a stated dose splits it into two daily doses (Nazimko 2012); no study compares single and split regimens.
  • Genetic polymorphisms: No pharmacogenetic data guide dosing; APOE ε4 status is of theoretical interest because of predicted promoter binding (Khavinson 2021), but no dose adjustment exists.
  • Sex differences: Human dosing reports enrolled mostly men (Bashkireva 2012), and in mice, spine density rose in both sexes but mature-spine gains appeared only in males (Khavinson 2021); no sex-specific dosing exists.
  • Age: Human use spans 41–83 years (Meshchaninov 2015) without age-based dose adjustment.
  • Baseline biomarkers: In rats, per the developers’ review, animals with low baseline antioxidant-enzyme activity responded and resistant animals did not (Khavinson 2020); low baseline blood counts call for closer monitoring rather than dose change.
  • Pre-existing conditions: Human protocols targeted organic brain syndrome (Meshchaninov 2015), brain-injury after-effects (per the developers’ review, Khavinson 2020) and occupational strain (Bashkireva 2012); no protocol exists for healthy adults or for kidney or liver impairment.

Discontinuation & Cycling

  • Short-term use: Russian protocols use defined courses, such as two weeks at 100 µg twice daily (Nazimko 2012), rather than continuous lifelong use; long-term continuous use is unstudied.
  • Withdrawal effects: None reported in human studies; no study has looked for rebound symptoms after stopping.
  • Tapering: Not applicable; no dependence or receptor adaptation has been described, so courses end abruptly in practice.
  • Cycling: Repeating courses several times a year is common bioregulator practice, not evidence-based; no study shows that cycling preserves efficacy or that tolerance develops.

Sourcing and Quality

  • Two product types: Oral capsules and tablets listed as a dietary supplement in Russia (RLS register), versus lyophilized (freeze-dried) injectable vials sold internationally as research chemicals without human-use quality standards.
  • Identity and purity testing: A batch certificate of analysis with HPLC purity (commonly ≥98%) and mass-spectrometry confirmation of the expected molecular mass (about 418 daltons) verifies that the vial contains Glu-Asp-Arg.
  • Sterility for injectables: Endotoxin (bacterial toxin) and sterility testing, reconstitution with bacteriostatic water and refrigerated storage reduce infection and degradation risks that research-grade suppliers do not guarantee.
  • Reputable brands: No pinealon product has been tested by ConsumerLab or USP (United States Pharmacopeia), so no brand can be called independently verified; the Russian oral product is the form used in the published human studies.
  • Storage of oral products: The Russian capsules are stored dry, protected from light at 2–25 °C, with a five-year shelf life (RLS register).

Practical Considerations

  • Time to effect: The cited oral protocol reassessed adaptation indices after two weeks (Nazimko 2012); sleep effects are reported anecdotally within days. No study has measured onset systematically.
  • Pitfall – the name: Pinealon is not a pineal-gland extract and has no shown effect on melatonin; it derives from the brain-cortex drug Cortexin (Kuznik 2019). It is often confused with epitalon or pineal extracts.
  • Pitfall – product form: Russian oral capsules and Western injectable vials differ in route, dose and quality control; human data exist only for oral use (Nazimko 2012).
  • Pitfall – combining agents: Starting several bioregulators or sleep aids at once makes it impossible to attribute benefits or adverse events to pinealon.
  • Regulatory status (US): Pinealon does not appear on FDA’s Category 2 list of nominated compounding substances with safety risks (FDA Category 2 list); US sellers market it as a research chemical.
  • Regulatory status (Russia): Listed as a dietary supplement in capsule and tablet forms, not as a medicine (RLS register).
  • Accessibility: Outside Russia, pinealon is mainly available from research-chemical vendors of variable quality; no insurer or health system covers it, so no payer has a financial stake in its adoption or rejection.

Interaction with Foundational Habits

  • Sleep: Potentiating (claimed, unproven). Users report longer REM sleep (Huberman Lab episode); the proposed route is increased cortical serotonin, a melatonin precursor, seen only in cell culture (Khavinson 2014). Evening dosing is common practice; wearable REM tracking before and during a course tests the claim individually.
  • Nutrition: None known. Oral pinealon consists of three dietary amino acids, and no nutrient depletion has been reported. Whether food competes with its proposed gut transporters is unknown (Khavinson 2023); taking capsules apart from protein-rich meals is a common-practice choice.
  • Exercise: Indirect, unstudied. Developer work proposes that EDR modulates expression of irisin (an exercise-induced muscle hormone) (Khavinson 2016), and rats showed better hypoxia tolerance (Kozina 2008). No study tests effects on training adaptation or workout timing.
  • Stress management: Potentiating in occupational reports. Peptide courses improved psychoemotional scores in truck drivers (Bashkireva 2012); in old rats under hypoxia or cold, pinealon raised brain adrenergic (adrenaline-type) transmitter and serotonin levels (Mendzheritsky 2015). Cortisol effects are unmeasured.

Monitoring Protocol & Defining Success

Baseline: Before a first course, a CBC with white-cell differential, ALT (alanine aminotransferase, a liver-injury enzyme) and serum creatinine (a kidney-function marker) establish personal reference values. Because no validated biomarker of pinealon’s effect exists, a short computerized cognitive test and two weeks of wearable sleep tracking provide the baseline for the outcomes it is used for.

Ongoing: The CBC is repeated at the end of each two-week course, then every 6 months during repeated courses; ALT and creatinine are repeated every 6–12 months; cognitive and sleep measures are repeated at the end of each course. Success is a sustained, personally meaningful improvement in cognitive or sleep measures with blood counts unchanged from baseline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
White blood cells with differential 3.4–9.6 ×10⁹/L (standard reference range) Safety check: blood-cell suppression stops use Prompted by the CD34+ decline (Meshchaninov 2015); no fasting needed; laboratory-specific ranges apply
Hemoglobin Men 13.2–16.6 g/dL; women 11.6–15.0 g/dL (standard reference range) Safety check: falling values stop use Drawn with the white-cell count; hydration and altitude shift values
Platelets Men 135–317 ×10⁹/L; women 157–371 ×10⁹/L (standard reference range) Safety check: falling values stop use Drawn with the white-cell count; compare with own baseline
ALT 7–55 U/L (standard reference range) Safety check: rise signals liver injury from an untested compound or contaminant Strenuous exercise within 48 hours before testing can raise values
Serum creatinine Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL (standard reference range) Safety check: rise signals kidney injury from an untested compound Morning draw; recent high meat intake or creatine supplements raise values

Qualitative markers:

  • Sleep quality: Perceived sleep depth and wearable-estimated REM duration compared with the two-week baseline.
  • Cognitive clarity: Memory, focus and word-finding in daily tasks, alongside repeated scores on the same cognitive test.
  • Mental fatigue and stress tolerance: Energy across demanding workdays and recovery after stress.
  • Injection-site status: Redness, swelling or pain at injection sites for users of injectable products.

Emerging Research

  • Registered trials: A ClinicalTrials.gov search in October 2026 found no registered pinealon trial, so no NCT ID (registry number) exists. A placebo-controlled cognitive or sleep trial would be the first test able to confirm or overturn the Low-graded human claims.
  • Independent mouse screening: VivoArchitect’s eight-week preprint (Marín-Jerez 2026) is the first non-Russian animal test. Larger, longer studies in older mice of both sexes could strengthen the working-memory signal or show it was noise; funding came partly from a pinealon-linked token.
  • Human induced-neuron aging models: In neurons converted from elderly donors’ skin cells, EDR reduced oxidative DNA damage and lengthened dendrites but left mitochondria, lysosomes and p16 (a cell-aging marker) unchanged (Kraskovskaya 2024), a mixed picture.
  • Senescence studies: In neurons derived from fetal stem cells, the abstract reports reduced senescence (cell-aging) markers for the related peptides AEDG (Ala-Glu-Asp-Gly) and KED (Lys-Glu-Asp) but not for EDR (Sakhenberg 2025), weakening the case for EDR as an anti-senescence agent.
  • Alzheimer’s disease models: Spine-density gains without significant memory-circuit improvement (Khavinson 2021; its 2025 correction replaced duplicated figures, conclusions unchanged: Khavinson 2025) leave disease-modifying claims open; the group’s review positions EDR as a multitarget candidate (Ilina 2024).
  • Pharmacokinetics: Transporter docking (Khavinson 2023) is the only work on uptake. A human pharmacokinetic study would show whether oral doses reach the blood intact, strengthening or undermining every oral-use claim.

Conclusion

Pinealon is a three-amino-acid peptide created by a Russian research group that views tiny peptides as regulators of gene activity in aging tissue. For health-focused adults interested in protecting the aging brain, its appeal rests on laboratory and animal findings: less chemical damage to nerve cells from unstable oxygen molecules, better tolerance of low oxygen, preserved nerve-cell connections in Alzheimer-type models and, in one independent mouse study, a hint of better working memory.

Human evidence is thin. A few small Russian reports describe better memory, mental performance, stress tolerance and biological-age scores, but none used a placebo comparison, several mixed pinealon with a related peptide, and the brain-injury results are available only through the developers’ own summary. Popular claims about longer dreaming sleep rest on personal accounts alone.

The safety record is also incomplete. No serious harms have been reported, yet one small study noted fewer circulating blood-forming stem cells and a rise in a laboratory sign of cell-damaging oxygen activity, and nobody has measured how long the peptide survives in the body or what years of use might do. Injectable products sold as research chemicals add uncertainty about identity and purity.

Nearly all research comes from the institute that developed pinealon and has an interest in its adoption, and the one independent animal study was funded partly through a digital token linked to pinealon. Pinealon remains experimental, its promise resting mainly on laboratory work, with unmeasured uncertainty about both benefit and risk.

Top - Benefits - Risks - Protocol